ZyVersa Therapeutics(US:ZVSA)2026-03-31 20:54Financial Performance - ZyVersa Therapeutics reported a net loss of $25.0 million for the year ended December 31, 2025, compared to a net loss of $9.4 million for the previous year, representing a 165.1% increase in losses[187][202]. - The company incurred a net loss of $25.0 million for the year ended December 31, 2025, with an accumulated deficit of $137.6 million as of the same date[212]. - Total operating expenses for 2025 were $25.5 million, a significant increase of 179.0% compared to $9.1 million in 2024[202]. - Future operating losses are expected to continue for several years as the company develops its product candidates and seeks marketing approval[219]. Research and Development - Research and development expenses decreased by approximately $0.7 million or 37.4% to $1.1 million in 2025, primarily due to fewer consultants and a pause in the VAR200 clinical trial[203]. - The impairment of in-process research and development was $18.6 million in 2025, a significant decline from the previous year when no impairment was recorded[205]. - The company recorded an $18.6 million impairment charge for in-process research and development, reflecting a full impairment of the intangible asset due to a decline in market capitalization[229]. Cash and Financing - As of December 31, 2025, ZyVersa had an accumulated deficit of approximately $137.6 million and cash of $0.1 million, indicating a critical need for additional financing[187][211]. - Current assets as of December 31, 2025, were $0.348 million, while current liabilities were $12.735 million, resulting in a working capital deficiency of $12.387 million[210]. - Cash requirements for current liabilities as of December 31, 2025, are approximately $12.7 million for accounts payable and accrued expenses[214]. - The company expects to continue incurring significant expenses related to the development of its product candidates VAR 200 and IC 100, and will seek additional financing through equity or debt[188][189]. - The company plans to raise additional capital through equity, equity-linked securities, or debt to fund continued development of its product candidates[216]. - The company’s cash on hand is only sufficient to fund operations on a month-to-month basis, indicating a need for additional financing[215]. Corporate Governance and Compliance - The company expects to incur significant costs related to corporate governance and compliance as a public company[219]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay compliance with certain accounting standards[223]. - The company does not have any off-balance sheet arrangements that could materially affect its financial conditions[225]. Stock and Market Activity - ZyVersa's common stock was delisted from Nasdaq on October 6, 2025, and began trading on the OTCQB under the symbol "ZVSA" on July 28, 2025[190]. - The company has no arrangements in place for acquisitions or in-licensing but continues to evaluate strategic transactions to enhance its product pipeline[220].